Abciximab-induced thrombocytopenia: correct management

Year 2022, Volume: 39 Issue: 2, 581 - 583, 18.03.2022

Engin Kelkitli , Aslı Odabaşı Giden , Derya Deniz Kürekçi , Mehmet Turgut

Abstract

Thrombocytopenia is a possible side effect of routinely administered medical agents. Abciximab is one of the three potent intravenous glycoprotein IIb/IIIa receptor inhibitors (along with eptifibatide and tirofiban) that have shown significant positive outcomes when used in patients with intracoronary thrombus. The use of abciximab was associated with the risk of thrombocytopenia. In this case, the development of thrombocytopenia and treatment management were reported after the use of abciximab.

Keywords

Abciximab, glycoprotein IIb/IIIa receptor inhibitors, side effect, thrombocytopenia

References

• 1. Nowakowski, K., et al., Abciximab-induced thrombocytopenia: management of bleeding in the setting of recent coronary stents. J Interv Cardiol, 2008. 21(1): p. 100-5.
• 2. George, J.N. and R.H. Aster, Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program, 2009: p. 153-8.
• 3. Arnold, D.M., et al., A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost, 2013. 11(1): p. 169-76.
• 4. Park, S., et al., Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Korean Circ J, 2013. 43(8): p. 557-60.
• 5. Aster, R.H., et al., Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. J Thromb Haemost, 2006. 4(3): p. 678-9.
• 6. Golden, T., et al., Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention. BMJ Case Rep, 2017. 2017.
• 7. Curtis, B.R., et al., Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost, 2004. 2(6): p. 985-92.
• 8. Aster, R.H. and D.W. Bougie, Drug-induced immune thrombocytopenia. N Engl J Med, 2007. 357(6): p. 580-7.
• 9. Llevadot, J., S.A. Coulter, and R.P. Giugliano, A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis, 2000. 9(2): p. 175-80.
• 10. Giupponi, L., et al., Delayed, severe thrombocytemia after abciximab infusion for primary angioplasty in acute coronary syndromes: Moving between systemic bleeding and stent thrombosis. Platelets, 2015. 26(5): p. 498-500.
• 11. Arnold, D.M., et al., Approach to the diagnosis and management of drug-induced immune thrombocytopenia. Transfus Med Rev, 2013. 27(3): p. 137-45.
• 12. Bakchoul, T. and I. Marini, Drug-associated thrombocytopenia. Hematology Am Soc Hematol Educ Program, 2018. 2018(1): p. 576-583.
• 13. Piątek, Ł., et al., Delayed severe abciximab-induced thrombocytopenia: A case report. Heart Lung, 2016. 45(5): p. 464-5.